Cytomed Therapeutics Limited (GDTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | |
| Assets | |
| Current Assets | |
| Cash & Cash Equivalents | 1,179 |
| Receivables | 682 |
| TOTAL | $1,861 |
| Non-Current Assets | |
| PPE Net | 2,632 |
| Investments And Advances | 179 |
| Other Non-Current Assets | 14 |
| TOTAL | $2,825 |
| Total Assets | $3,900 |
| Liabilities | |
| Current Liabilities | |
| Short Term Debt | 2,787 |
| Accounts payable and accrued liabilities | 311 |
| Other current liabilities | 3 |
| TOTAL | $3,107 |
| Non-Current Liabilities | |
| Long Term Debt | 350 |
| TOTAL | $355 |
| Total Liabilities | $3,462 |
| Shareholders' Equity | |
| Common Shares | 6,650 |
| Retained earnings | -6,116 |
| Other shareholders' equity | -97 |
| TOTAL | $437 |
| Total Liabilities And Equity | $3,899 |